Month: October 2022

On April 19, 2019, Ku, Yi-Yin; Chan, Vincent S.; Christesen, Alan; Grieme, Timothy; Mulhern, Mathew; Pu, Yu-Ming; Wendt, Michael D. published an article.Recommanded Product: 3-Nitro-4-chlorobenzenesulfonamide The title of the article was Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor. And the article contained the following:

The process development of a new synthetic route leading to an efficient and robust synthetic process for venetoclax (1: the active pharmaceutical ingredient (API) in Venclexta) is described. The redesigned synthesis features a Buchwald-Hartwig amination to construct the core ester 23c (2 tert-Bu ester) in a convergent fashion by connecting two key building blocks (4c and 26), which is then followed by a uniquely effective saponification reaction of 23c using anhydrous hydroxide generated in situ to obtain 2. Finally, the coupling of the penultimate core acid 2 with sulfonamide 3 furnishes drug substance 1 with consistently high quality. The challenges and solutions for the key Pd-catalyzed C-N cross-coupling will also be discussed in detail. The improved synthesis overcomes many of the initial scale-up challenges and was accomplished in 46% overall yield from 3,3-dimethyldicyclohexanone (6), more than doubling the overall yield of the first generation route. The new process was successfully implemented for producing large quantities of 1 with >99% area purity. The experimental process involved the reaction of 3-Nitro-4-chlorobenzenesulfonamide(cas: 97-09-6).Recommanded Product: 3-Nitro-4-chlorobenzenesulfonamide

The Article related to venetoclax large scale synthesis buchwald hartwig amination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 3-Nitro-4-chlorobenzenesulfonamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On June 30, 2017, Zhang, Yinsheng; Gao, Yong; Ren, Jing; Wang, Qinglin; Wang, Zhao published a patent.Related Products of 16230-24-3 The title of the patent was 2,4-Disubstituted pyrimidine compounds as EGFR or/and ALK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

The invention relates to 2,4-disubstituted pyrimidine compounds of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and application thereof in treating diseases induced by EGFR or/and ALK. Compounds of formula I wherein X and Y are independently N and CH; R1 is H, halo, CF3, CN; R2 and R6 are independently H, C1-6 alkoxy; R3 and R5 are independently H, acroylamino; R4 is (un)substituted 3- to 8-membered heterocyclic ring, -Z-(CH2)1-4-NR9R10; R7 is H, C1-6 alkoxy, -Z-(CH2)1-4-NR9R10, (un)substituted piperazinyl; R9 and R10 are independently H and C1-4 alkyl; Z is O, S, NH and derivatives; and their pharmaceutically acceptable salts as EGFR or/and ALK inhibitors in the treatment of diseases thereof, are claimed. Compounds of formula I were prepared by using condensation and reduction as the key steps. All the invention compounds were evaluated for their EGFR or/and ALK inhibitory activity. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Related Products of 16230-24-3

The Article related to pyrimidine preparation egfr alk inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On May 21, 2021, Xu, Chang; Shen, Fang-Qi; Feng, Gaofeng; Jin, Jian published an article.COA of Formula: C6H13NO The title of the article was Visible-Light-Induced α-Amino C-H Bond Arylation Enabled by Electron Donor-Acceptor Complexes. And the article contained the following:

Enabled by electron donor-acceptor complexes, a novel visible-light-induced α-amino C-H bond arylation protocol, without a photoredox catalyst, was disclosed. The protocol does not require any transition metal, oxidant, or exclusion of oxygen or moisture. A direct irradiation of the mixture of tertiary amines and benzonitriles with visible light in N,N-diethylethanamide in the presence of Cs2CO3 afforded α-arylated amines in good to excellent yields. The experimental process involved the reaction of N,N-Diethylacetamide(cas: 685-91-6).COA of Formula: C6H13NO

The Article related to tertiary amine benzonitrile photochem regioselective arylation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.COA of Formula: C6H13NO

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On June 23, 2016, Ombrato, Rosella; Garofalo, Barbara; Mangano, Giorgina; Capezzone de Joannon, Alessandra; Corso, Gaia; Cavarischia, Claudia; Furlotti, Guido; Iacoangeli, Tommaso published a patent.Formula: C11H9NO3 The title of the patent was Antibacterial compounds having broad spectrum of activity. And the patent contained the following:

The present invention relates to novel antibacterial compounds, I (R1 = H, halo, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkyl-OH, carboxy, amido, etc.; L1 σ-bond, CH2, O, NH, etc.; Y = C1-6 alkylenyl, NH-C1-6 alkylenyl, C4-5 cycloaklenyl, etc.; L2 = σ-bond, NH, NH-C1-6 alkylenyl, etc.,; A = fused bicyclic group, etc.; B = fused bicyclic or tricyclic functional group, etc.; G1, G2 = CH, N, etc.), pharmaceutical compositions containing them and their use as antimicrobials. The experimental process involved the reaction of 2-(Oxiran-2-ylmethyl)isoindoline-1,3-dione(cas: 5455-98-1).Formula: C11H9NO3

The Article related to piperazine chromene derivative preparation antibacterial activity, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C11H9NO3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On July 3, 2008, Aissaoui, Hamed; Boss, Christoph; Gude, Markus; Koberstein, Ralf; Sifferlen, Thierry published a patent.HPLC of Formula: 65645-88-7 The title of the patent was Preparation of 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives as orexin receptor antagonists. And the patent contained the following:

Title compounds represented by the formula I [wherein X = CH2 or O; R1 = independently phenyl; R2 = alkyl, alkenyl, halo, etc.; R3 = alkyl, alkoxymethyl or halo; R4 = alkyl; and pharmaceutically acceptable salts thereof] were prepared as orexin (OX) receptor antagonists. For example, II was provided in a multi-step synthesis starting from Knoevenagel condensation of 3,4-dimethylbenzaldehyde with malonic acid. I showed antagonistic activity on OX1 and OX2 receptors in intracellular calcium measurements. The experimental process involved the reaction of (S)-2-Hydroxy-N-methyl-2-phenylacetamide(cas: 65645-88-7).HPLC of Formula: 65645-88-7

The Article related to tetrahydroimidazopyrazine preparation orexin receptor antagonists, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 65645-88-7

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On January 13, 2022, Steadman, David; Atkinson, Benjamin N.; Zhao, Yuguang; Willis, Nicky J.; Frew, Sarah; Monaghan, Amy; Patel, Chandni; Armstrong, Emma; Costelloe, Kathryn; Magno, Lorenza; Bictash, Magda; Jones, E. Yvonne; Fish, Paul V.; Svensson, Fredrik published an article.Reference of 2-(4-Methylbenzamido)acetic acid The title of the article was Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity. And the article contained the following:

Notum is a neg. regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Inhibitors of Notum could be of use in diseases where dysfunctional Notum activity is an underlying cause. A docking-based virtual screen (VS) of a large com. library was used to short-list 952 compounds for exptl. validation as inhibitors of Notum. The VS was successful with 31 compounds having an IC50 < 500 nM. A critical selection process was then applied with two clusters and two singletons selected for hit validation. Optimization of I guided by structural biol. identified potent inhibitors of Notum activity that restored Wnt/β-catenin signaling in cell-based models. The [1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one series represent a new chem. class of Notum inhibitors and the first to be discovered by a VS campaign. These results demonstrate the value of VS with well-designed docking models based on X-ray structures. The experimental process involved the reaction of 2-(4-Methylbenzamido)acetic acid(cas: 27115-50-0).Reference of 2-(4-Methylbenzamido)acetic acid

The Article related to triazolopyridazinone preparation carboxylesterase notum inhibitor screening, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Three Or More Hetero Atoms and other aspects.Reference of 2-(4-Methylbenzamido)acetic acid

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On March 22, 2022, Chen, Yong; Zhuang, Xiaoxiao published a patent.Related Products of 16230-24-3 The title of the patent was Preparation of rociletinib as epidermal cell growth factor receptor mutation inhibitor. And the patent contained the following:

The present invention relates to preparation of rociletinib as epidermal cell growth factor receptor mutation inhibitor. In particular, the preparation method comprises of following steps; (a) substitution reaction between 1-[4-(4-amino-3-methoxyphenyl)piperazin-1-yl]ethan-1-one and di-tert-Bu dicarbonate under the action of a base and an organic solvent to obtain tert-Bu (4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)carbamate; (b) substitution reaction of step (a) product and 2,4-dichloro-5-(trifluoromethyl)pyrimidine under the action of a base and an organic solvent to obtain tert-Bu (4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)(4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)carbamate; (c) substitution reaction of step (b) product and N-(3-aminophenyl)prop-2-enamide under the action of base and an organic solvent to obtain tert-Bu (4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)(4-((3-acrylamidophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)carbamate, and (d) hydrolysis reaction reaction of step (c) product under the action of an acid and an organic solvent to obtain the compound rociletinib. The preparation method of the epidermal cell growth factor receptor mutation inhibitor of the present invention has the advantages that the raw materials required for each step are cheap, easy to purchase, and the synthesis route is short, no isomers are produced, the intermediates are easy to sep. and purify, no column chromatog. is required, and the obtained product has high purity, high atom utilization, high yield, convenient purification, safe and simple reaction, and can be industrially produced. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Related Products of 16230-24-3

The Article related to rociletinib preparation epidermal cell growth factor receptor mutation inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On January 27, 2022, Wu, Hao; Wu, Wenmao; Li, Ling; Zhang, Zhan; Wang, Feng; Yuan, Ding; Wu, Yunfei; Chen, Qiang; Han, Han; Guo, Jing; Lan, Hong; Ding, Lieming; Wang, Jiabing published a patent.Category: amides-buliding-blocks The title of the patent was Piperidine-spiro-fused heterocyclic compounds as SHP2 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

The invention relates to piperidine-spiro-fused heterocyclic compounds of formula I, which are serving as an Src homol. region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitors, as well as to their pharmaceutical compositions thereof, the preparation method therefor, and the use in treating an SHP2 mediation disease. The compounds of formula I exert effects by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis. Compounds of formula I wherein the dotted double bond is either a single bond, or a double bond; ring A is (un)saturated 5- to 10-membered (hetero)cyclic ring; ring C is (un)saturated 5- to 10-membered heterocyclic ring, C6-10 aryl, 5- to 10-membered heteroaryl; each Rc is independently H, halo, CN, NO2, SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, etc.; two of the Rc may be taken together with the atom attached to form C3-8 cycloalkyl, 3- to 10-membered heterocyclic ring, C6-10 aryl, 5- to 10-membered heteroaryl, etc.; T is (CRc1Rc2)0-3; Rc1 and Rc2 are independently H, halo, C1-4 alkly, -OR5; Rc1Rc2 may be taken together with the atom attached to form C3-6 cycloalkyl, 3- to 6-membered heterocyclic ring; each R1 is independently H, halo, CN, NO2, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, etc.; X is O, NH and derivatives, SO0-2, CO, -CO-O-, -CO-NH- and derivatives, etc.; M is O, NH and derivatives, (un)substituted CH; Y1 and Y2 are independently NH and derivatives, (un)substituted CH; each R4 is independently H, halo, CN, NO2, C1-8 alkyl, C2-8 alkenyl, etc.; R5 is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkenyl, etc.; and their pharmaceutically acceptable salts, deuterium,stereoisomers, chelates, prodrugs as SHP2 inhibitors in the treatment of diseases thereof, are claimed. Example compound II was prepared by using spirocyclization, imination, reduction, cross-coupling as the key steps. All the invention compounds were evaluated for their SHP2 inhibitory activity. The experimental process involved the reaction of 2-Fluoro-4-hydroxybenzamide(cas: 1133122-96-9).Category: amides-buliding-blocks

The Article related to piperidine spiro fused heterocyclic preparation shp2 inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: amides-buliding-blocks

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On May 15, 2020, Hardouin, Christophe; Baillard, Sandrine; Bariere, Francois; Craquelin, Anthony; Grandjean, Mathieu; Janvier, Solenn; Le Roux, Stephane; Penloup, Christine; Russo, Olivier published an article.Quality Control of 3-Nitro-4-chlorobenzenesulfonamide The title of the article was Multikilogram Synthesis of a Potent Dual Bcl-2/Bcl-xL Antagonist. 2. Manufacture of the 1,3-Diamine Moiety and Improvement of the Final Coupling Reaction. And the article contained the following:

This paper describes the synthesis of kilogram quantities of the sulfonamide moiety I involved in a coupling reaction with acid moiety II to provide batches of drug candidate III for preclin. studies and first-in-human clin. trials. A first approach relying on a chiral separation furnished the desired enantiomer of 1,3-diamine IV, precursor of sulfonamide I. An enantiomeric synthesis of IV using the Ellman’s chiral auxiliary coupled with an aza-Reformatsky reaction to control the stereochem. is also discussed. Coupling conditions of the final step involving EDCI to provide III under a cGMP process are detailed. An alternative approach using N-(1-methanesulfonyl)benzotriazole is also presented. The experimental process involved the reaction of 3-Nitro-4-chlorobenzenesulfonamide(cas: 97-09-6).Quality Control of 3-Nitro-4-chlorobenzenesulfonamide

The Article related to acylsulfonamide diamine telescoped process aza reformatsky coupling chemoselective amination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 3-Nitro-4-chlorobenzenesulfonamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On December 30, 2009, Aissaoui, Hamed; Boss, Christoph; Koberstein, Ralf; Siegrist, Romain; Sifferlen, Thierry published a patent.Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide The title of the patent was 5,6,7,8-Tetrahydroimidazo[1,5-a]pyrazine compounds as orexin receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

The invention relates to 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives of formula I and to the use of such compounds as medicaments, especially as orexin (OX) receptor antagonists. Compounds of formula I wherein R4 is C1-4 alkyl; when R3 is cyclopropyl, then R2 is halo, CF3, C1-4 alkyl and vinyl, R1 is substituted phenyl; when R3 is C3-6 cycloalkyl-C1-4 alkyl, then R2 is halo, R1 is substituted phenyl; when R3 is -SO2-C1-4 alkyl, then R2 is halo, R1 is substituted phenyl; when R3 is -S-C1-4 alkyl, then R2 is halo, CF3 and vinyl, R1 is substituted phenyl; when R3 is C1-4 alkyl, then R2 is -SO0-2-C1-4 alkyl, R1 is substituted phenyl; when R3 is C1-4 alkoxy, then R2 is CF3, R1 is substituted phenyl; when R3 is CF3, then R2 is C1-4 alkyl, R1 is substituted phenyl; when R3 is C1-4 alkyl, then R2 is halo, R1 is substituted phenyl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared via N-alkylation of 1-chloro-8-[2-(4-chloro-3-fluorophenyl)ethyl]-3-cyclopropyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine with toluene-4-sulfonic acid (S)-methylcarbamoylphenyl Me ester. All the invention compounds were evaluated for their OX receptor antagonistic activity. From the assay, it was determined that II exhibited the IC50 values of 43 nM and 11 nM against OX1 and OX2, resp. The experimental process involved the reaction of (S)-2-Hydroxy-N-methyl-2-phenylacetamide(cas: 65645-88-7).Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide

The Article related to tetrahydro imidazopyrazine compound preparation orexin receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics